Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2026-03-03 @ 9:19 AM
Study NCT ID:
NCT00599820
Status:
TERMINATED
Last Update Posted:
2024-06-03
First Post:
2006-06-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000793', 'term': 'Angioid Streaks'}, {'id': 'D020256', 'term': 'Choroidal Neovascularization'}], 'ancestors': [{'id': 'D012164', 'term': 'Retinal Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}, {'id': 'D015862', 'term': 'Choroid Diseases'}, {'id': 'D014603', 'term': 'Uveal Diseases'}, {'id': 'D009389', 'term': 'Neovascularization, Pathologic'}, {'id': 'D008679', 'term': 'Metaplasia'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}}, 'statusModule': {'whyStopped': 'Poor accrual', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2005-11', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-05', 'completionDateStruct': {'date': '2006-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-05-31', 'studyFirstSubmitDate': '2006-06-30', 'studyFirstSubmitQcDate': '2008-01-23', 'lastUpdatePostDateStruct': {'date': '2024-06-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2008-01-24', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2005-11', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'BCVA'}, {'measure': 'Fluoresceine Angiography'}, {'measure': 'Optical Coherence Tomography'}]}, 'conditionsModule': {'keywords': ['Angioid Streaks', 'Choroidal Neovascularization', 'Bevacizumab'], 'conditions': ['Angioid Streaks', 'Choroidal Neovascularization']}, 'descriptionModule': {'briefSummary': 'Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks', 'detailedDescription': 'A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Clinical diagnosis of Angioid Streaks\n* Choroidal neovascularization associated\n* Untreated patients or patients treated once with PDT\n\nExclusion Criteria:\n\n* Ocular surgery excepting uncomplicated phacoemulsification\n* Glaucoma or any other ocular pathology'}, 'identificationModule': {'nctId': 'NCT00599820', 'briefTitle': 'Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks', 'organization': {'class': 'OTHER', 'fullName': 'Asociación para Evitar la Ceguera en México'}, 'officialTitle': 'OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab', 'orgStudyIdInfo': {'id': 'APEC 010'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Intravitreal Bevacizumab', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'zip': '04030', 'city': 'Mexico City', 'state': 'Mexico City', 'country': 'Mexico', 'facility': 'Asociación para Evitar la Ceguera en México (APEC)', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}], 'overallOfficials': [{'name': 'Adriana Solís-Vivanco, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Asociación para Evitar la Ceguera en México'}, {'name': 'Jans Fromow-Guerra, MD PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Asociación para Evitar la Ceguera en México'}, {'name': 'Mariana Martínez-Castellanos, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Asociación para Evitar la Ceguera en México'}, {'name': 'Elizabeth Reyna-Castelán, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Asociación para Evitar la Ceguera en México'}, {'name': 'Myriam Hernández-Rojas, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Asociación para Evitar la Ceguera en México'}, {'name': 'Griselda Alvarez-Rivera, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Asociación para Evitar la Ceguera en México'}, {'name': 'Hugo Quiroz-Mercado, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Asociación para Evitar la Ceguera en México'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Asociación para Evitar la Ceguera en México', 'class': 'OTHER'}}}}